Apply
Company Summary
FL62, Inc. is a privately held, early-stage biotechnology company developing a novel platform to design, manipulate, and deliver microbes to solve major needs in human health and sustainability. FL62 was founded by Flagship Pioneering, an innovative enterprise that conceives, creates, funds, and develops first-in-category life sciences companies. Since its launch in 2000, the firm has applied its hypothesis-driven innovation process to originate and foster over 75 scientific ventures, resulting in $19 billion in aggregate value and 500 issued patents. These companies include Seres Therapeutics (NASDAQ:MCRB), Moderna (MRNA), Syros Pharmaceuticals (SYRS), Rubius Therapeutics (RUBY), Axcella Health, Evelo Biosciences (EVLO), Indigo, and Inari Agriculture. Since inception, Flagship has capitalized its growing portfolio with nearly $1 billion coming from $2.5 billion of aggregate investor capital committed.
Position Summary
The Head of R